Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Accumulated Expenses (2023 - 2025)

Monte Rosa Therapeutics' Other Accumulated Expenses history spans 3 years, with the latest figure at $4.4 million for Q1 2025.

  • For Q1 2025, Other Accumulated Expenses rose 104.68% year-over-year to $4.4 million; the TTM value through Mar 2025 reached $4.4 million, up 104.68%, while the annual FY2024 figure was $3.4 million, 100.72% up from the prior year.
  • Other Accumulated Expenses reached $4.4 million in Q1 2025 per GLUE's latest filing, up from $3.4 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $4.4 million in Q1 2025 to a low of $1.3 million in Q3 2024.
  • Average Other Accumulated Expenses over 3 years is $2.7 million, with a median of $2.5 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 55.19% in 2024, then soared 104.68% in 2025.
  • A 3-year view of Other Accumulated Expenses shows it stood at $1.7 million in 2023, then soared by 100.72% to $3.4 million in 2024, then surged by 31.81% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Other Accumulated Expenses are $4.4 million (Q1 2025), $3.4 million (Q4 2024), and $1.3 million (Q3 2024).